Over 3 years, SGLT2 inhibitors were safely associated with a nearly one third reduction in the risk for serious liver events.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data from the AVONELLE-X and SALWEEN ...

Genentech’s initial investment in North Carolina is estimated at more than $700m and is part of Roche’s $50bn commitment to ...

OMass Therapeutics partners with Genentech to advance innovative treatments for inflammatory bowel disease, leveraging their ...

Oxford, UK-based biotech OMass Therapeutics today announced it has entered into an exclusive collaboration and license ...

Roche’s Genentech unit has handed over $20 million in upfront cash for the license to Omass Therapeutics’ preclinical inflammatory bowel disease (IBD) program. | Roche’s Genentech unit has handed over ...

Generative AI, once seen as a tool for writers and artists, is now reshaping the high-stakes world of pharma regulation.

Research from Deloitte has shown that 82% of CEOs report burnout and 96% report a negative impact on their mental health.

Collaboration leverages OMass’ OdyssionTM platform for the continued development of oral small molecules against a ...

To date, Vabysmo is approved in more than 100 countries for nAMD and diabetic macular edema (DME), and in more than 60 countries for macular edema following retinal vein occlusion (RVO). More than ...

Gilead and Amgen are among the lengthening list of big pharma companies that have pledged billions of dollars in new builds ...

Among the three FDA-approved treatments, SPINRAZA and ZOLGENSMA are leading the market, with SPINRAZA securing a notable ...